about
GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.Localization of LRRK2 to membranous and vesicular structures in mammalian brainTen years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinicIdentification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motifRNA-Seq optimization with eQTL gold standards.Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes.Exaggerated CpH methylation in the autism-affected brain.Dynamic and redundant regulation of LRRK2 and LRRK1 expression.Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodentsAbrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.Identification of a novel gene linked to parkin via a bi-directional promoter.Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease.Genetics of parkin-linked disease.PGC-1α provides a transcriptional framework for synchronous neurotransmitter release from parvalbumin-positive interneurons.Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism.Defining the contribution of CNTNAP2 to autism susceptibility.Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activitiesLeucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury.Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.LRRK2 autophosphorylation enhances its GTPase activity14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.LRRK2 inhibition attenuates microglial inflammatory responsesUrinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers.The NINDS Parkinson's disease biomarkers program.Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.Hyperactivity and cortical disinhibition in mice with restricted expression of mutant huntingtin to parvalbumin-positive cells.Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.LRRK2 in Parkinson's disease: function in cells and neurodegeneration.Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.N-myc regulates parkin expression.Parkin is not regulated by the unfolded protein response in human neuroblastoma cells.The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.LRRK2 secretion in exosomes is regulated by 14-3-3.Identification of bona-fide LRRK2 kinase substrates.Identification and characterization of the human parkin gene promoter.
P50
Q21144926-1523C3B6-90CA-4F4A-BC21-C01ECF7AF1ADQ24298689-B49A161A-6418-4F86-8CF2-13A10BC578AAQ24318643-DB73098F-725E-4B1F-A219-83D0D1BB609CQ27007413-D576AD8A-45EF-4BCD-853C-25DEFB28DD8AQ28475942-09B4B71D-16DA-4364-944F-60B55C33DC68Q30564266-226EE14D-4B86-49D0-9746-B84B64920D66Q30607522-DF222477-5060-492F-9227-1AFA82DF9612Q30841912-524D2E2A-339B-47C9-951D-0329140BE8AFQ33307626-83ACEAEC-C10D-4BFC-9F6C-267A8F08B1C3Q33825413-2F2BB899-5561-4C51-8F01-2B3F98F24CBEQ33835006-82FE3E5D-DCAB-4B6F-B03A-FAB0A0CB6FD6Q34172709-3BA31EB4-841E-4C08-B5C2-81DF10F23ED6Q34189618-355B0578-6F93-4E8F-AA04-0A9E982B5DD0Q34290333-17FD3BA2-BFC6-41AB-885A-7E49490EE359Q34383492-F5FCC149-681C-45EF-A977-1CD6C8A5404EQ34533693-7D154433-EF93-4F98-9837-9BD742D299E4Q34552787-DE7D82F6-7F41-4333-BFE7-E748B15C6A28Q34731122-187F4A55-2B76-4E7C-83B8-8F735CF96CC7Q35023479-5FFD7093-D1F2-4FB9-8872-810B0A2B55F3Q35172817-49E4C761-8750-49E7-B56B-8732637F3099Q35766417-92513899-C6C6-466D-A329-DA82732474F2Q35925767-620B1A6F-49BC-4B49-BAE8-C4D301207FB3Q36385349-3612F027-DD91-4674-B7C0-AADEB53FC67EQ36402571-8D22189C-F3F4-4C48-9940-51E94C772F39Q36493605-DD552ED7-1E0D-49B4-8ED8-8DF980BEB3E9Q36706040-9D3030C9-1209-455B-B3AE-D36007209B08Q36777618-F6E06E29-0114-4B77-A14D-23E9BB588816Q36929535-BAB2D04B-5706-42F0-BB45-A5EDAD4D1FFDQ37096048-2D1C8EDF-0C45-4CE3-AFB3-4E0C4DA78166Q37313530-F9090519-2CAF-4C44-96CA-EDE60B9394EFQ37424600-C86CA791-887F-460C-9C2C-187E4F1F4C82Q37479332-0AF3473A-D64E-4D51-8023-9B5CE10A4BA9Q37608630-D44184C1-3C45-4FD5-AF70-EFF1F603566DQ39686532-08D6B6EB-AC42-47EF-9225-0DD2CE65FF1CQ40567942-25FACD81-7B0E-4AAF-AB8B-153FEB7485CDQ40657291-0615171E-B9A4-4BCE-B82A-8691876D30A6Q42116736-BEBD638F-E919-413F-A70A-51D329DF7155Q42149865-6000CE28-32D7-4B23-9B3B-A69542927459Q42363197-0C5A27C1-23C8-4060-B40C-0E1AA01597CDQ42659344-D47CA178-89EA-493D-9D35-715BED140194
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrew B West
@nl
Andrew B West
@sl
Andrew B. West
@en
Andrew B. West
@es
type
label
Andrew B West
@nl
Andrew B West
@sl
Andrew B. West
@en
Andrew B. West
@es
altLabel
Andrew West
@en
prefLabel
Andrew B West
@nl
Andrew B West
@sl
Andrew B. West
@en
Andrew B. West
@es
P106
P108
P1153
8099960500
P21
P31
P496
0000-0002-3034-4061